Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price.
The position represents 1.99% of 13F assets under management (AUM).
Travere Therapeutics is not among the fund’s top five holdings after the trade.
These 10 stocks could mint the next wave of millionaires ›
According to a Securities and Exchange Commission (SEC) filing dated January 20, 2026, Palisades Investment Partners, LLC reported initiating a new position in Travere Therapeutics (NASDAQ:TVTX).
The fund acquired 137,768 shares, with the estimated value of the trade at $5.26 million based on the quarterly average share price. The new stake’s quarter-end value also totaled $5.26 million, reflecting the company’s share price at period close.
This new position accounts for 1.99% of Palisades Investment Partners’ $264.72 million in reportable U.S. equity assets as of December 31, 2025
Top five holdings after the filing:
NASDAQ: STRL: $29.86 million (11.3% of AUM)
NYSE: SPXC: $23.04 million (8.7% of AUM)
NASDAQ: WGS: $11.34 million (4.3% of AUM)
NASDAQ: KRYS: $10.54 million (4.0% of AUM)
NASDAQ: MMYT: $9.80 million (3.7% of AUM)
As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, up 50.89% over the past year and outperforming the S&P 500 by 34.01 percentage points.
Metric | Value |
|---|---|
Price (as of market close January 16, 2026) | $27.87 |
Market Cap | $2.46 billion |
Revenue (TTM) | $435.83 million |
Net Income (TTM) | ($88.54 million) |
Travere Therapeutics generates revenue from commercialized rare disease therapies, including Chenodal, Cholbam, and Thiola/Thiola EC, with additional pipeline assets such as Sparsentan and TVT-058 in clinical development.
The company operates a biopharmaceutical business model, focusing on the identification, development, and commercialization of treatments for rare and specialty diseases, leveraging proprietary research and strategic collaborations.
Travere Therapeutics serves patients with rare metabolic and renal disorders, targeting high-need indications through partnerships with advocacy organizations and research institutions.
Travere Therapeutics, Inc. is a biotechnology company specializing in the development and commercialization of therapies for rare diseases. The company leverages a diversified portfolio of approved products and a pipeline targeting high-need indications, supported by strategic partnerships and clinical research initiatives.
Travere’s focus on rare disease markets positions it to address unmet medical needs and drive growth through targeted innovation and commercialization.
